Lab results taken 24 hours prior to first treatment:

• WBC 8.4
  
• ANC 6.2
  
• Hgb 149
  
• Platelets 149
  

Weight: 87 kg Height: 160 cm

1. Which of the following best describes the BC Cancer benefit status of CISplatin and etoposide?

1. They are both Class I drugs and do not require special approval prior to dispensing. 
   
2. They are both Class I drugs and require special approval prior to dispensing.
   
3. They are both Restricted drugs and case-by-case Compassionate Access Program (CAP) approval must be obtained prior to dispensing.
   
4. CISplatin is Class I drug, but etoposide is Restricted and requires special approval prior to dispensing. 
   

2. What is the patient’s BSA, using the Mosteller equation?

1. 1.97 m² 
2. 1.9 m² 
3. 1.96 m² 
   
4. 2 m² 

3. Given the calculated BSA, what should the dosing regimen be?

1. 49 mg CISplatin IV and 197 mg etoposide IV daily × 3 days 
2. 48 mg CISplatin IV and 190 mg etoposide IV daily × 3 days 
3. 49 mg CISplatin IV and 196 mg etoposide IV daily × 5 days 
4. 50 mg CISplatin IV and 200 mg etoposide IV daily × 5 days 

4. Based on the protocol, when should J.P. receive his second cycle of chemotherapy?

1. In one week
2. In two weeks
3. In three weeks
4. In four weeks

5. What are the minimum hematologic lab values J.P. would have to exhibit to continue with his current dose of etoposide?

1. ANC greater than 1.5 and platelets greater than 100
2. ANC less than 1.5 and platelets less than 100
3. ANC greater than 1.0 and platelets greater than 75
4. ANC = 1.5 and platelets = 100